• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC14D9C filed by Elevation Oncology Inc.

    6/9/25 8:10:15 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELEV alert in real time by email
    SC14D9C 1 tm2517439d2_sc14d9c.htm SC14D9C

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14D-9

     

    SOLICITATION/RECOMMENDATION STATEMENT

    UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Elevation Oncology, Inc.

    (Name of Subject Company)

     

    Elevation Oncology, Inc.

    (Name of Persons Filing Statement)

     

    COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE

    (Title of Class of Securities)

     

    28623U101

    (CUSIP Number of Class of Securities)

     

    Tammy Furlong

    101 Federal Street, Suite 1900

    Boston, Massachusetts

    (716) 371-1135

     

    With copies to:

     

    Robert Freedman , Esq.

    David Michaels, Esq.

    Ryan Mitteness, Esq.

    Fenwick and West LLP

    401 Union Street, Floor 5

    Seattle, WA

    (206) 389-4510

    (Name, address, and telephone numbers of person authorized to receive notices and communications

    on behalf of the persons filing statement)

     

    x Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

     

    The information set forth under Items 1.01, 5.02, 5.07, 7.01 and 9.01 of the Current Report on Form 8-K filed by Elevation Oncology, Inc. on June 9, 2025 (including all exhibits attached thereto) is incorporated herein by reference.

     

     

     

     

     

    Get the next $ELEV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELEV

    DatePrice TargetRatingAnalyst
    3/24/2025$5.00 → $1.00Overweight → Equal-Weight
    Stephens
    3/21/2025$1.00Outperform → Market Perform
    Leerink Partners
    3/21/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/21/2025$0.70Overweight → Neutral
    Piper Sandler
    1/3/2025Outperform
    William Blair
    5/31/2024$10.00Overweight
    Piper Sandler
    5/14/2024$8.00Overweight
    Stephens
    3/1/2024$7.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $ELEV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Elevation Oncology downgraded by Stephens with a new price target

      Stephens downgraded Elevation Oncology from Overweight to Equal-Weight and set a new price target of $1.00 from $5.00 previously

      3/24/25 8:34:27 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Elevation Oncology from Outperform to Market Perform and set a new price target of $1.00

      3/21/25 8:03:34 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology downgraded by Citizens JMP

      Citizens JMP downgraded Elevation Oncology from Mkt Outperform to Mkt Perform

      3/21/25 8:03:24 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right

      BOSTON, June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ("Concentra"), whereby Concentra will acquire Elevation Oncology for $0.36 in cash per share of Elevation Oncology common stock ("Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (

      6/9/25 8:00:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

      -- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting -- -- Expects to file IND application for EO-1022 in 2026 -- -- Cash runway into 2H 2026 -- BOSTON, May 15, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2025, and provided recent business updates. "We recently presented preclinical proof-of-concept data for EO-1022, reaffirming its potential as a differentiated HER3 ADC, an

      5/15/25 7:30:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

      -- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors -- -- On-track to file IND application in 2026 -- BOSTON, April 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical proof-of-concept data for its novel HER3 antibody-drug conjugate (ADC), EO-1022. The data will be presented in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, b

      4/25/25 1:00:00 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Leadership Updates

    Live Leadership Updates

    See more
    • Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

      BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology. "Both are extremely experienced drug developers, who have contributed to the advancement and approval of multiple targeted therapies for the treatment of cancer. On behalf of the Board,

      3/4/24 7:30:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

      BOSTON, Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors. Dr. Mootz is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations to Elevation Oncology's Board of Directors. "We are pleased to welcome Darcy to the Elevation Oncology board, as she is a uniquely qualified leader, who has experience crafting late-stage development str

      1/22/24 7:30:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

      NEW YORK, July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced today the appointment of Joseph Ferra, M.B.A., as its Chief Executive Officer. Mr. Ferra was previously Interim Chief Executive Officer and Chief Financial Officer. Mr. Ferra will also join the Elevation Oncology Board of Directors. In addition, the Company announced the appointment of Tammy Furlong, M.B.A., C.P.A., as Chief Financial Officer, promoted from her previous role as Vice President of Finance and Accounting

      7/13/23 8:00:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Sandler Alan B.

      4 - Elevation Oncology, Inc. (0001783032) (Issuer)

      6/9/25 4:30:42 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Mootz Darcy

      4 - Elevation Oncology, Inc. (0001783032) (Issuer)

      6/9/25 4:25:07 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Elms Steve

      4 - Elevation Oncology, Inc. (0001783032) (Issuer)

      6/9/25 4:20:33 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

      SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      11/14/24 7:50:19 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

      SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      11/14/24 7:05:59 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

      SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      11/14/24 6:45:37 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    SEC Filings

    See more
    • SEC Form SC14D9C filed by Elevation Oncology Inc.

      SC14D9C - Elevation Oncology, Inc. (0001783032) (Subject)

      6/9/25 8:10:15 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Elevation Oncology, Inc. (0001783032) (Filer)

      6/9/25 8:05:29 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elevation Oncology Inc.

      SCHEDULE 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      5/15/25 4:27:14 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Financials

    Live finance-specific insights

    See more
    • Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

      -- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK, respectively; expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 2H 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30

      8/6/24 7:10:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

      -- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer ---- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/hypoesthesia --  -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 ---- Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 ---- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON, Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective ca

      8/6/24 7:00:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

      Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801)Expands pipeline to now include two clinical stage precision oncology candidates for patients with genomically defined solid tumors, including those with Claudin18.2 overexpressionCompany expects to initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 (SYSA1801) in 2023Management to host an investor conference call and webcast today at 5:00 p.m. ET NEW YORK, July 28, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, tod

      7/28/22 8:45:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care